Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia

Abstract EN

Myelodysplastic syndrome (MDS) is cytogenetically heterogeneous and retains variable risk for acute myeloid leukemia transformation.

Though not yet fully understood, there is an association between genetic abnormalities and defects in gene expression.

The functional role for infrequent cytogenetic alteration remains unclear.

An uncommon chromosomic abnormality is the presence of the Philadelphia (Ph) chromosome.

Here, we report a patient with Ph+ MDS treated with low dose Dasatinib who achieved hematologic response for 7 months.

In addition, we also examined the English literature on all de novo Ph + MDS cases between 1996 and 2015 to gain insight into clinical features and outcome.